3Savelieva I, Camm J. Update on atrial fibrillation: part Ⅰ.Clin Cardiol, 2008,31 : 55-62.
4Savelieva I, Camm J. Update on atrial fibrillation: part Ⅱ. Clin Cardiol,2008,31 : 102-108.
5Wyse D G. Anticoagulation in atrial fibrillation: a contemporary viewpoint. Heart Rhythm, 2007,4(3 Suppl):S34-S39.
6DeSilvey D L. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial. Am J Geriatr Cardiol, 2006,15:326-327.
7Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF Ⅱ: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol, 2003,41:1445-1451.
8Testa L, Andreotti F, Biondi Zoccai G G, et al. Ximelagatran/melagatran against conventional anticoagulation: a metaanalysis based on 22,639 patients. Int J Cardiol, 2007,122: 117-124.
9Kaul S, Diamond G A, Weintraub W S. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol. 2005,46 : 1986-1995.
10Eriksson B I, Dahl O E, Rosencher N, et al. Dabigatran etexitate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, non-inferiority trial. Lancet, 2007,370 : 949-956.
7Go AS, Hylek EM, Borowsky LH, et al. Warfarin use a- mong ambulatory patients with nonvalvular atrial fibrilla- tion:the anticoagulation and risk factors in atrial fibrilla- tion(ATRIA) study[,J]. Ann Intern Med, 1999,131(12) : 927- 934.
8Wan Y, Heneghan C,Perera R,et al. Anticoagulation con- trol and prediction of adverse events in patients with atrial fibrillation : a systematic review[J]. Circ Cardiovasc Qual Outcomes, 2008,1 (2) : 84-91.
9Hart RG, Pearce LA, Aguilar MI. Meta-analysis: an tithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007,146(12) :857-867.
10Goto S,Bhatt DL, Rother J, et al. Prevalence, clinical pro- file,and cardiovascular outcomes of atrial fibrillation pa- tients with atherothrombosis[,J]. Am Heart J, 2008,156 (5) :855-863.
